1. Home
  2. KRNT vs DRUG Comparison

KRNT vs DRUG Comparison

Compare KRNT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kornit Digital Ltd.

KRNT

Kornit Digital Ltd.

N/A

Current Price

$16.80

Market Cap

728.7M

Sector

Industrials

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

N/A

Current Price

$22.92

Market Cap

778.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRNT
DRUG
Founded
2002
2019
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Pharmaceuticals and Biotechnology
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
728.7M
778.4M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
KRNT
DRUG
Price
$16.80
$22.92
Analyst Decision
Buy
Strong Buy
Analyst Count
5
9
Target Price
$25.00
★ $123.23
AVG Volume (30 Days)
★ 315.0K
251.2K
Earning Date
11-18-2026
08-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.48
N/A
Revenue Next Year
$7.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.26
$18.10
52 Week High
$19.78
$123.75

Technical Indicators

Market Signals
Indicator
KRNT
DRUG
Relative Strength Index (RSI) 44.42 26.49
Support Level $14.56 N/A
Resistance Level $16.80 $58.93
Average True Range (ATR) 0.68 4.28
MACD -0.19 -3.30
Stochastic Oscillator 30.20 13.87

Price Performance

Historical Comparison
KRNT
DRUG

About KRNT Kornit Digital Ltd.

Kornit Digital Ltd is a developer and provider of digital solutions for the printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software, and value-added services that enable large-scale printing of short-run complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink, and other consumables, and services, including software subscriptions. The company geographically operates in the U.S., EMEA, Asia Pacific, and other countries. It derives maximum revenue from the U.S.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: